The Immunology, Inflammation, and Infectious Disease (3i) Initiative at University of Utah Health was formally established in 2017 on the premise that a better understanding of the three "I"s and their connections will fundamentally change the way we think about disease. Since our launch, the 3i Initiative has brought together a campus-wide community of over 200 investigators representing nearly every department at the University of Utah. Our community focuses on a wide range of topics, including, Inflammatory Bowel Disease, HIV/AIDS, Sepsis, Malaria, Cancer Immunotherapy, Influenza, and Multiple Sclerosis amoung others. Through the efforts of the 3i Initiative, we work to make fundamental discoveries that ultimately improve patient care.
In addition to our ongoing efforts, the 3i Initiative served as the leader for the University of Utah's research response to the COVID-19 Pandemic. Harnessing the unique collaborative nature of the University of Utah, we were able to mount an incredible response resulting in more than 600 publications and more than $60M in extramural funding. Learn more about the University of Utah and the 3i Initiative's COVID-19 research response.
Disease modeling research suggests that for some cholera outbreaks, prescribing antibiotics more aggressively could slow or stop the spread of the disease and even reduce the likelihood of antibiotic resistance.
Leading scientists joined forces to explore how the microbes that live in and on our bodies can be leveraged to provide real-world solutions and improve health care.
Research has found that C. difficile, one of the most contagious hospital-acquired infections, spreads more than three times more than previously thought, moving covertly from surface to surface.
The results could ultimately help doctors reduce the risk of type 1 diabetes—or potentially even restore pancreas function in adulthood—by providing gut microbes that help the pancreas grow and heal.
